Leishmaniasis
=============

Leishmaniasis is a vector-borne parasitic disease whose clinical manifestations range from local cutaneous lesions (cutaneous leishmaniasis, CL) to life-threatening visceral disease (visceral leishmaniasis, VL), mainly as a result of differences among *Leishmania* species. *L. pifanoi* is responsible for CL, characterized by a localized infection at the site of inoculation by the vector, while *L. infantum* causes VL due to parasite dissemination into internal organs. *Leishmania* parasites exist in two developmental stages. The flagellated promastigote is transmitted with the bite of the sand fly (insect vector) to the mammalian host, where it transforms into the amastigote stage. *Leishmania* amastigotes infect mononuclear phagocytes, where their intracellular location allows them to subvert the effector and regulatory functions of these cells ([@bib26]). Since epidermal Langerhans cells and dermal dendritic cells (DCs) contribute to immunosurveillance of the skin ([@bib8]; [@bib54]) and are located in proximity to the site of parasite delivery, their role in the initiation of *Leishmania*-specific immune responses is an active area of research.

*Leishmania* host cells
=======================

To attain a successful infection, *Leishmania* needs to subvert the host immune response from the early steps after its inoculation. In the natural course of infection, these events occur in the dermis, where DCs may act as host cells for *Leishmania*, independently of the pathological outcome of the infection ([@bib52]). In this regard, Langerhans cells within cutaneous lesions are parasitized by *Leishmania* in vivo in both human and experimental murine CL ([@bib14]; [@bib56]). Studies on the interactions of *Leishmania* with murine or human DC have not yet clearly determined the range of parasite forms that these cells can internalize ([@bib3]; [@bib11]; [@bib14]; [@bib49]; [@bib51]; [@bib57]; [@bib58]; [@bib66]; [@bib69]; [@bib77]; [@bib81], [@bib82]) or their influence on parasite survival.

Although *Leishmania* species might differentially subvert DC effector function ([@bib4]; [@bib15]; [@bib17]; [@bib36]; [@bib45]; [@bib49]; [@bib64]; [@bib71]; [@bib81]), the receptors involved in the *Leishmania*--DC interaction remain largely undefined and could be critical for this process. In contrast, several macrophage receptors have been identified which mediate binding and subsequent uptake of *Leishmania* promastigotes ([@bib13]; [@bib68]). In this regard, lipophosphoglycan (LPG) and the metalloproteinase gp63 bind to complement receptor type 3 (CR3), mannose-fucose, and fibronectin receptors on macrophages ([@bib13]; [@bib22]; [@bib39]; [@bib59]; [@bib74]; [@bib84]). However, the receptors implicated in amastigote uptake by DC and macrophages are poorly characterized, mainly due to the fact that isolation or in vitro culture of this intracellular form is difficult. The availability of axenic cultures has now opened the possibility of addressing the identification of *Leishmania* amastigotes receptors on macrophages and DCs ([@bib6]; [@bib10]; [@bib24]; [@bib25]; [@bib38]; [@bib42]).

*Leishmania* interaction with dendritic cells: exploiting DC-SIGN
=================================================================

Macrophages and DCs express a wide variety of pathogen-associated molecular pattern receptors, including numerous C-type lectin and lectin-like receptors ([@bib28]; [@bib29]; [@bib53]). Since *Leishmania* spp. display an abundance of mannose-rich glycoconjugates on their surface that are important for parasite virulence ([@bib44]; [@bib31]), a reasonable hypothesis is that lectin--oligosaccharide interactions are involved in parasite recognition by mononuclear phagocytes. DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN, CD209) is a type II transmembrane C-type lectin expressed on DCs and macrophages, and was initially described as involved in cell--cell interactions through its capacity to bind ICAM-3 and ICAM-2 ([@bib32], [@bib33]; [@bib79]). The DC-SIGN extracellular domain comprises eight 23-residue tandem repeats and a C-terminal carbohydrate-recognition domain ([@bib55]). DC-SIGN is now known to be a receptor for HIV ([@bib34]; [@bib63]), *Ebola* virus ([@bib2]), *Schistosoma mansoni* ([@bib78]), *Sindbis* virus ([@bib48]) *Candida albicans* ([@bib16]) *Mycobacterium tuberculosis* ([@bib35]), Hepatitis C ([@bib83]), *Helicobacter pylori* ([@bib12]) and the fungal pathogen *Aspergillus fumigatus* ([@bib72]).

Most *Leishmania* amastigote-DC studies have been carried out with tissue-derived opsonized parasites, which might be bound via Fc and complement receptors, thus precluding the identification of opsonization-independent binding mechanisms. To analyze the participation of the receptor DC-SIGN in binding and internalization of *Leishmania*, we used axenic amastigotes ([@bib6]; [@bib62]), which are devoid of opsonizing antibodies. We first analyzed the interaction of *L. pifanoi* (that causes CL) axenic amastigote with K562-DC-SIGN transfectants and demonstrated that they are specifically recognized by DC-SIGN ([@bib18]). Subsequently, *L. pifanoi* amastigotes were found to bind DC-SIGN on the surface of immature monocyte-derived dendritic cells (IMDDCs), an interaction that was dramatically reduced in the presence of anti-DC-SIGN blocking antibodies ([@bib18]). This set of results suggested an important role for DC-SIGN in the early stages of infection of DCs by *Leishmania*.

Since infection of immature dermal DCs is a common step shared by all *Leishmania* species, we next analyzed the capacity of IMDDCs to bind other *Leishmania* life cycle forms and species. Our results ([@bib19]) underscored the relevance of the DC-SIGN--*Leishmania* interaction in both VL (*L. infantum*) and CL (*L. pifanoi*), as amastigotes and promastigotes from both species exhibited DC-SIGN-interaction capacity. Since the membrane composition of the parasite changes throughout its life cycle ([@bib7]; [@bib85]), we tested the ability of DC-SIGN to bind the three main life cycle forms of the parasite (amastigotes, procyclic promastigotes and metacyclic promastigotes). Amastigotes and metacyclic promastigotes showed the strongest DC-SIGN-dependent interaction with IMDDC ([Fig. 1](#fig1){ref-type="fig"} ). Moreover, the avidity for DC-SIGN increased in the transition from procyclic (non-infective) to metacyclic (infective) promastigotes (i.e., procyclic and metacyclic promastigotes, respectively) ([Fig. 1](#fig1){ref-type="fig"}). Hence, the avidity of the different forms of the parasite for DC-SIGN appears to correlate with their virulence. On the other hand, a much lower ability for DC-SIGN recognition was observed in *Leishmania major* promastigotes ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Summary of experiments evaluating the contribution of DC-SIGN to immature monocyte-derived dendritic cell binding to different *Leishmania* life cycle forms and species. Immature monocyte-derived DCs were prepared as previously described, left untreated or pre-treated 10 min at 25 °C with the blocking anti-DC-SIGN monoclonal antibody ([@bib67]) and incubated with CFSE-labeled parasites at a 1:5 ratio for 1 h at 35 °C. Afterward, the percentage of cells with bound parasites was quantified by flow cytometry and the contribution of DC-SIGN (%) was calculated as: 100−((% MR-1-treated cells with bound parasites×100)/% untreated cell with bound parasites).

*DC-SIGN ligands on Leishmania:* LPG is one of the most abundant glycoconjugates exposed on the cell surface of promastigotes, but scarcely expressed on amastigotes, and plays a pleiotropic role through the life cycle of *Leishmania* ([@bib1]; [@bib21]; [@bib47]; [@bib61]; [@bib70]; [@bib75]; [@bib76]). This molecule is characterized by a high mannose content, and has been proposed to mediate promastigote interaction with DCs via DC-SIGN ([@bib5]). However, our results indicate that LPG is not an important *Leishmania* ligand for DC-SIGN because: (1) LPG is strongly down-regulated in amastigotes ([@bib43]; [@bib44]; [@bib75]), which exhibit the highest DC-SIGN-binding ability; (2) LPG was unable to block *Leishmania* binding to DC-SIGN for all species and parasite developmental stages assayed; and (3) the LPG-defective *L. donovani* promastigotes (R2D2) bind to DC-SIGN-expressing cells. Furthermore, since LPG-defective promastigotes bound DC-SIGN with higher avidity than their wild-type counterparts, LPG might in fact mask other promastigote membrane ligands with affinity for DC-SIGN ([@bib19]).

*Leishmania ability to modulate the DC maturation state*: Conflicting results have been obtained on the ability of various *Leishmania* species to induce DC maturation ([@bib4]). It is currently unknown whether this variability is due to variations in the experimental conditions or truly reflects species-specific or strain-specific interactions between *Leishmania* and DC. Since *Leishmania* spp. express highly polymorphic cell surface molecules, the DC response might vary according to the *Leishmania* species examined ([@bib11]; [@bib30]; [@bib40]; [@bib49]; [@bib52]; [@bib81], [@bib82]). We have evaluated the ability of *L. infantum* to alter the maturation state of IMDDC. Unlike LPS, *L. infantum* amastigotes, which bind to IMDDC via DC-SIGN, did not affect the cell surface expression of CD83, CD86 or MHC II, commonly considered as DC maturation parameters. Therefore, our results suggest that non-opsonized *L. infantum* amastigotes are unable to induce IMDDC maturation, at least during a 48-hour period ([Fig. 2A](#fig2){ref-type="fig"} ). Moreover, LPS induced maturation of IMDDCs infected with *L. infantum* amastigotes ([Fig. 2A](#fig2){ref-type="fig"}), indicating that the parasites do not inhibit the capacity of DCs to be matured by other pathogen-derived products. The failure of IMDDC to mature in response to *Leishmania* capture and entry might represent a parasite strategy to avoid immunosurveillance and to allow their establishment and multiplication before the onset of immune responses. On the other hand, *L. infantum* amastigotes did not induce CCR7-directed IMDDC migration but inhibited the CCR7-dependent migration induced upon LPS maturation ([Fig. 2B](#fig2){ref-type="fig"}). These data are in agreement with previous results demonstrating that cytokines abundantly produced during *Leishmania* infection (e.g., IL-10) down-regulate CCR7 expression ([@bib4]). Therefore, *Leishmania* might prevent the establishment of T cell-mediated immunity by interfering with the migratory properties of DCs.Fig. 2Effect of *Leishmania* infection on dendritic cells maturation and migration. Immature monocyte-derived DCs were left untreated or pretreated for 1 h with LPS before adding or not *L. infantum* axenic amastigotes, and then incubated for 48 h. Afterward, cells were phenotypically characterized (A), and subjected to migration assays towards the CCR7 ligand CCL19 (B). Three independent experiments were performed with similar results, and a representative experiment is shown.

*L-SIGN: a receptor implicated in VL*: L-SIGN is a close homologue of DC-SIGN (77% amino acid sequence identity) that is expressed on human liver and lymph node sinusoidal endothelial cells ([@bib73]). Like DC-SIGN, L-SIGN recognizes and binds high-mannose glycans, binds to ICAM-3 ([@bib9]), and recognizes carbohydrate structures on pathogens such as ManLAM on *M. tuberculosis* ([@bib50]) and high-mannose moieties on HIV-1, HCV and Ebola. Besides, L-SIGN has been described as a receptor for severe acute respiratory syndrome coronavirus ([@bib46]). Unlike DC-SIGN, L-SIGN does not bind to the fucose-containing Lewis^x^ antigens, suggesting that L-SIGN-expressing liver endothelial cells and lymph node are not involved in capture and internalization of Lewis^x^-containing pathogens such as *H. pylori* and *S. mansoni* ([@bib80]). Besides, binding to L-SIGN is not reversible at low pH, suggesting that L-SIGN does not release internalized ligand in low-pH vesicles and that L-SIGN is degraded upon internalization ([@bib37]). Because of their similar ligand specificity but differential tissue location, we have compared the capacity of DC-SIGN and L-SIGN to bind axenic amastigotes from *L. pifanoi* (responsible for CL), and *L. infantum* (responsible for VL). Binding experiments with Jurkat cells stably transfected with DC-SIGN or L-SIGN indicated that *L. infantum* amastigotes specifically bound to both DC-SIGN and L-SIGN, whereas *L. pifanoi* amastigotes were unable to bind to L-SIGN ([Fig. 3](#fig3){ref-type="fig"} ). Therefore, only VL-causing parasites (*L. infantum*) appear to be recognized by L-SIGN. These results suggest that L-SIGN recognition of the distinct *Leishmania* species might play a role in the outcome of the parasite infection (CL vs. VL).Fig. 3*Leishmania infantum* binding to Jurkat cells expressing L-SIGN. L-SIGN-transfected Jurkat cells (Jurkat-L-SIGN), Jurkat-DC-SIGN and mock-transfected Jurkat cells ([@bib2]) were left untreated or pretreated with receptor-specific blocking antibodies, and then incubated at 35 °C with the indicated CFSE-labeled parasites (1:5 cell:parasite ratio), or left uninfected ([@bib18]). The percentage of cells with bound parasites was quantified by flow cytometry. Three independent experiments were performed with similar results, and a representative experiment is shown.

To further evaluate the relevance of L-SIGN in binding of *Leishmania* species causing VL, human hepatic sinusoidal endothelial cells (HSEC) were isolated from hepatic surgery donors, using a modification (Iñigo Martinez and Fernando Vidal-Vanaclocha, unpublished information) of previously described isolation procedures ([@bib23]; [@bib41]). Incubation of HSEC with axenic amastigotes showed that *L. infantum* amastigotes bound strongly to HSEC, whereas no binding was observed with *L. pifanoi* amastigotes ([Fig. 4](#fig4){ref-type="fig"} ). In addition, the HSEC-*L. infantum* amastigote interaction was reduced in the presence of a blocking monoclonal antibody against L-SIGN ([Fig. 4](#fig4){ref-type="fig"}). These results confirmed the ability of VL-causing amastigotes to interact with L-SIGN. Given the mechanism described for the hepatitis C virus ([@bib20]), it is tempting to speculate that L-SIGN-mediated capture of *L. infantum* by HSEC could result in transinfection of Kupffer cells, which are the final targets of VL-causing *Leishmania* parasites ([@bib27]; [@bib60]).Fig. 4*L. infantum* binding to hepatic sinusoidal endothelial cells (HSEC) is partially mediated by L-SIGN. Human HSEC were isolated from liver biopsies, and subjected to binding assays with *L. pifanoi* or *L. infantum* axenic amastigotes, as described ([@bib18]). After incubation and washing, cells were photographed (HSEC, hepatic sinusoidal endothelial cells; K, Kupffer cells). Two independent experiments were performed with similar results, and a representative experiment is shown.

Concluding remarks
==================

Taken together, the present work demonstrates that the C-type lectins DC-SIGN and L-SIGN are broad *Leishmania* receptors that differentially bind the distinct infective forms and species of the parasite. A deeper knowledge of the *Leishmania*--DC/L-SIGN interactions, and the subsequent immune consequences, may pave the way for the design of new therapeutic approaches against leishmaniasis. The recent description that macrophage treated with IL-4 (alternatively activated macrophages) also express DC-SIGN ([@bib65]) could be of major importance, due to the fact that the expression of this cytokine correlates with the pathology of the disease, and hence increases the potential relevance of these C-type lectins in leishmaniasis.
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